AU2022284369A1 - Inhibitors of bruton's tyrosine kinase and methods of their use - Google Patents

Inhibitors of bruton's tyrosine kinase and methods of their use Download PDF

Info

Publication number
AU2022284369A1
AU2022284369A1 AU2022284369A AU2022284369A AU2022284369A1 AU 2022284369 A1 AU2022284369 A1 AU 2022284369A1 AU 2022284369 A AU2022284369 A AU 2022284369A AU 2022284369 A AU2022284369 A AU 2022284369A AU 2022284369 A1 AU2022284369 A1 AU 2022284369A1
Authority
AU
Australia
Prior art keywords
formula
compound
iii
alkyl
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022284369A
Other languages
English (en)
Inventor
Sriram Balasubramanian
Ivo CORNELISSEN
Yue GUO
Jocelyn H. Leu
Xin MIAO
Kathryn E. Packman
James Alexander PALMER
Ulrike Philippar
Navin Rao
Mark S. Tichenor
Jennifer D. Venable
John J.M. Wiener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2022284369A1 publication Critical patent/AU2022284369A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022284369A 2021-06-04 2022-06-02 Inhibitors of bruton's tyrosine kinase and methods of their use Pending AU2022284369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196843P 2021-06-04 2021-06-04
US63/196,843 2021-06-04
PCT/IB2022/055154 WO2022254371A1 (en) 2021-06-04 2022-06-02 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (1)

Publication Number Publication Date
AU2022284369A1 true AU2022284369A1 (en) 2024-01-25

Family

ID=82214195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022284369A Pending AU2022284369A1 (en) 2021-06-04 2022-06-02 Inhibitors of bruton's tyrosine kinase and methods of their use

Country Status (14)

Country Link
US (1) US20230013755A1 (https=)
EP (1) EP4346834A1 (https=)
JP (1) JP2024520630A (https=)
KR (1) KR20240019214A (https=)
CN (1) CN117412753A (https=)
AU (1) AU2022284369A1 (https=)
BR (1) BR112023025459A2 (https=)
CA (1) CA3220015A1 (https=)
CL (2) CL2023003564A1 (https=)
IL (1) IL308951A (https=)
JO (1) JOP20230310A1 (https=)
MX (1) MX2023014435A (https=)
TW (1) TW202317127A (https=)
WO (1) WO2022254371A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964976B1 (en) 2023-09-12 2024-04-23 King Faisal University Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015008042A2 (pt) 2012-10-11 2017-07-04 Pharmacyclics Inc diagnósticos complementares para terapia com inibidor de quinase da família tec
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
IL308951A (en) 2024-01-01
EP4346834A1 (en) 2024-04-10
BR112023025459A2 (pt) 2024-02-27
CL2024002895A1 (es) 2025-02-14
CA3220015A1 (en) 2022-12-08
CN117412753A (zh) 2024-01-16
CL2023003564A1 (es) 2024-06-21
TW202317127A (zh) 2023-05-01
KR20240019214A (ko) 2024-02-14
WO2022254371A1 (en) 2022-12-08
US20230013755A1 (en) 2023-01-19
JOP20230310A1 (ar) 2023-11-29
MX2023014435A (es) 2024-03-08
JP2024520630A (ja) 2024-05-24

Similar Documents

Publication Publication Date Title
AU2021240244B2 (en) Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor
AU2020239751B2 (en) Crystalline forms of a Bruton's tyrosine kinase inhibitor
US20230013755A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
KR102054468B1 (ko) 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US20160022683A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
US20240238291A1 (en) Combinations for treatment of cancer
CN107530346A (zh) 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式
CA3223610A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
HK40107411A (zh) 布鲁顿氏酪氨酸激酶抑制剂及其使用方法
EA051432B1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
HK1249015B (en) Pharmaceutical formulations of bruton's tyrosine kinase inhibtor